Breakthroughs in Cancer Immunotherapy Webinar: Dr. Lawrence Fong, Can the Immune System See Colorectal Cancer?
On March 18, 2014, Lawrence Fong, M.D., an associate professor of medicine in the division of Hematology/Oncology at the University of California, San Francisco, discussed the importance of immune responses within colorectal cancers and how patients whose immune cells infiltrate their tumors have a better clinical outcome. Dr. Fong also talked about what the immune system could be seeing in colorectal cancer, as well as the developments in immunotherapy for colorectal cancer, namely cetuximab, vaccines, and immune checkpoint inhibitors.
Dr. Fong has been focused on developing immune-based therapies for cancers including prostate, kidney, melanoma, and colorectal cancers. He has been involved in pre-clinical and clinical studies with sipuleucel-T and anti-CTLA-4 antibodies. Dr. Fong currently leads a translational immunotherapy program at UCSF and also leads a research lab studying antigen-specific recognition of tumors in both mouse models and clinical trials. Current work includes developing biomarkers for immunotherapies that are associated with clinical responses or side effects. Dr. Fong obtained his M.D. at Stanford, completed internal medicine training at University of Washington, and oncology fellowship at Stanford. He currently serves on multiple NIH committees including the NCI CONC Study Section, NCI Investigational Drug Steering Committee (IDSC), and NCI Genitourinary Cancers Steering Committee (GUSC). He has served on the editorial board of the Journal of Clinical Oncology and currently serves as a senior editor for Cancer Immunology Research, a new journal from AACR in collaboration with the Cancer Research Institute.